Kenneth Galbraith
CIK: 0001567045
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Zymeworks Inc.
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectStock Option (Right to Buy)
216K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Sale(S)Direct30.4K shares at avg. $22.67$690K - Jan 12, 2026ZYME
Zymeworks Inc.
Exercise(M)Direct64K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectPerformance Stock Unit
222K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectRestricted Stock Unit
144K shares- - Jan 5, 2026ZYME
Zymeworks Inc.
Sale(S)Direct31.7K shares at avg. $25.10$795K - Jan 5, 2026ZYME
Zymeworks Inc.
Exercise(M)Direct47.7K shares- - Jan 5, 2026ZYME
Zymeworks Inc.
Sale(S)Direct22.7K shares at avg. $25.10$569K - Jan 5, 2026ZYME
Zymeworks Inc.
Exercise(M)Direct66.7K shares- - Dec 22, 2025ZYME
Zymeworks Inc.
Exercise(M)Direct100K shares- - Dec 22, 2025ZYME
Zymeworks Inc.
Sale(S)Direct47.5K shares at avg. $27.02$1.3M - Jan 10, 2025ZYME
Zymeworks Inc.
Award(A)DirectRestricted Stock Unit
192K shares- - Jan 10, 2025ZYME
Zymeworks Inc.
Award(A)DirectStock Option (Right to Buy)
288K shares- - Jan 6, 2025ZYME
Zymeworks Inc.
Exercise(M)Direct66.7K shares- - Jan 6, 2025ZYME
Zymeworks Inc.
Sale(S)Direct23.9K shares at avg. $14.92$356K - Jan 6, 2025ZYME
Zymeworks Inc.
Exercise(M)Direct47.7K shares- - Jan 6, 2025ZYME
Zymeworks Inc.
Sale(S)Direct33.4K shares at avg. $14.92$499K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 12, 2026 | ZYME Zymeworks Inc. | Award(A) Stock Option (Right to Buy) | 216,000 | - | - | Direct |
| Jan 12, 2026 | ZYME Zymeworks Inc. | Sale(S) | 30,424 | $22.67 | $689,819 | Direct |
| Jan 12, 2026 | ZYME Zymeworks Inc. | Exercise(M) | 64,000 | - | $0 | Direct |
| Jan 12, 2026 | ZYME Zymeworks Inc. | Award(A) Performance Stock Unit | 222,000 | - | - | Direct |
| Jan 12, 2026 | ZYME Zymeworks Inc. | Award(A) Restricted Stock Unit | 144,000 | - | - | Direct |
| Jan 5, 2026 | ZYME Zymeworks Inc. | Sale(S) | 31,686 | $25.10 | $795,220 | Direct |
| Jan 5, 2026 | ZYME Zymeworks Inc. | Exercise(M) | 47,668 | - | $0 | Direct |
| Jan 5, 2026 | ZYME Zymeworks Inc. | Sale(S) | 22,657 | $25.10 | $568,620 | Direct |
| Jan 5, 2026 | ZYME Zymeworks Inc. | Exercise(M) | 66,666 | - | $0 | Direct |
| Dec 22, 2025 | ZYME Zymeworks Inc. | Exercise(M) | 100,000 | - | - | Direct |
| Dec 22, 2025 | ZYME Zymeworks Inc. | Sale(S) | 47,528 | $27.02 | $1,284,311 | Direct |
| Jan 10, 2025 | ZYME Zymeworks Inc. | Award(A) Restricted Stock Unit | 192,000 | - | - | Direct |
| Jan 10, 2025 | ZYME Zymeworks Inc. | Award(A) Stock Option (Right to Buy) | 288,000 | - | - | Direct |
| Jan 6, 2025 | ZYME Zymeworks Inc. | Exercise(M) | 66,666 | - | $0 | Direct |
| Jan 6, 2025 | ZYME Zymeworks Inc. | Sale(S) | 23,885 | $14.92 | $356,462 | Direct |
| Jan 6, 2025 | ZYME Zymeworks Inc. | Exercise(M) | 47,666 | - | $0 | Direct |
| Jan 6, 2025 | ZYME Zymeworks Inc. | Sale(S) | 33,406 | $14.92 | $498,554 | Direct |
1-17 of 17 transactions
About Galbraith Kenneth
Galbraith Kenneth (SEC CIK 0001567045) files insider reports with the SEC as Chair & CEO of Zymeworks Inc. (ZYME).
Signal8 holds 5 ownership filings by Galbraith Kenneth, all Form 4s, filed between Jan 6, 2025 and Jan 12, 2026. Those filings report 17 transactions, from Jan 6, 2025 to Jan 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Galbraith Kenneth's filings is in MIDDLETOWN, DE.
Recent filings by Galbraith Kenneth
- Jan 12, 2026: Grant or award of ZYME derivative securities (Form 4, code A).
- Jan 12, 2026: Open-market sale of ZYME shares (Form 4, code S).
- Jan 12, 2026: Option exercise of ZYME shares (Form 4, code M).
- Jan 12, 2026: Grants or awards of ZYME derivative securities (2 lines, Form 4, code A).
- Jan 5, 2026: Open-market sale of ZYME shares (Form 4, code S).
Other insiders filing for Zymeworks Inc. (ZYME)
- Schayowitz Adam, EVP, Head of R&D
- Hollywood Mark, EVP & Chief Operating Officer
- Schneider Paul R, EVP, General Counsel
- Platshon Scott, EVP, Chief Business Officer
- Stafford Kristin, EVP, Chief Financial Officer
- Mekan Sabeen, SVP & Chief Medical Officer